Issue 113

Best-read Articles of 2022

The Psychedelics Newsletter is the sector’s best-read investment focused newsletter, with over 25,000 subscribers. Featuring in-depth market analysis and interviews with industry thought leaders, the weekly publication tracks innovations and milestones to identify commercial opportunities.

As psychedelic medicines progress through clinical trials, attention is increasingly turning to the commercialisation and adoption of psychedelic healthcare. For drug developers this involves identifying the treatment’s expected patient journey and collaborating with regulators, healthcare providers and payees to promote accessibility.

As we look ahead to 2023, below is a summary of the six best-read articles from The Psychedelics Newsletter in 2022.

PSYCHEDELIC HEALTHCARE VALUED AT £542 MILLION

The Psychedelics as Medicine Report revealed the industry is expected to exceed US$3 billion by 2026.

OREGON PSILOCYBIN SERVICES APPLICATIONS

Oregon Psilocybin Services begins accepting applications for psilocybin manufacturers, centres and facilitators.

BUSINESS AND INVESTMENT

Veterans Affairs report recognises potential of psychedelic medicine.

Canadian doctors may become thought leaders in psychedelic medicine.

Training programmes for therapists in psychedelic healthcare.

Psychedelic therapy at a crossroads in 2023.

The online prescription of ketamine.

Biomind creates sublingual 5-MeO-DMT formulation.

An overview of the benefits of ketamine-assisted therapy.

Clearmind enrols clinic for alcohol-use disorder study.

AGN Pharma establishes Algernon NeuroScience to advance DMT research.

There are now only five Super Early Bird tickets left for PSYCH Symposium: London 2023. Secure your ticket today at the discounted rate, before it is too late!

Super Early Bird tickets on sale for £249 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

The role of traditional music during psychedelic medicine ceremonies.

Single-dose psilocybin-assisted therapy in major depressive disorder.

BMI does not predict overall intensity of psychedelic experience.

Psychedelic medicines in the treatment of alcohol use disorder.

Subjective experiences of volunteers in Australian psilocybin trial.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Event partnership provides the opportunity to connect with a tailored audience ready to support the development of psychedelic healthcare, such as researchers, regulators and qualified investors.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

PARTNERSHIP OPPORTUNITIES

REGULATION AND LEGISLATION

The decriminalisation of psychedelic medicine in Colorado.

New York lawmakers file bill to decriminalise psychedelic medicine.

Psilocybin services in Oregon could generate US$165m a year.

The Psychedelics as Medicine Report provides industry intelligence, with an exclusive contribution from Angela Allbee, Psilocybin Services Section Manager at Oregon Health Authority.

COMPLIMENTARY DOWNLOAD

ARTICLES OF INTEREST

Eight times science exceeded expectations in 2022

2022 trends in health and wellness.

Scientific achievements at Imperial College London.

Side effects of ayahuasca reduce benefits.